Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-ACC Trial (niraparib + cisplatin in recurrent/metastatic adenoid cystic carcinoma)
2022-004188-25Phase 2Terminated
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and cisplatin in adenoid cystic carcinoma (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Overall Response Rate (ORR). Started Jan 2023; status: terminated.
02
Drugs
niraparibcisplatin
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2022-004188-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004188-25.